Edesa Net Receivables from 2010 to 2026
| EDSA Stock | USD 1.12 0.03 2.75% |
Net Receivables | First Reported 2009-12-31 | Previous Quarter 286.7 K | Current Value 642.9 K | Quarterly Volatility 1.2 M |
Check Edesa Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Edesa Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 127.3 K, Interest Expense of 993.4 K or Selling General Administrative of 3.7 M, as well as many indicators such as Price To Sales Ratio of 2.7 K, Dividend Yield of 0.0 or PTB Ratio of 115. Edesa financial statements analysis is a perfect complement when working with Edesa Biotech Valuation or Volatility modules.
Edesa | Net Receivables | Build AI portfolio with Edesa Stock |
Analyzing Edesa Biotech's Net Receivables over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Receivables has evolved provides context for assessing Edesa Biotech's current valuation and future prospects.
Latest Edesa Biotech's Net Receivables Growth Pattern
Below is the plot of the Net Receivables of Edesa Biotech over the last few years. It is Edesa Biotech's Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Edesa Biotech's overall financial position and show how it may be relating to other accounts over time.
| Net Receivables | 10 Years Trend |
|
Net Receivables |
| Timeline |
Edesa Net Receivables Regression Statistics
| Arithmetic Mean | 515,706 | |
| Geometric Mean | 180,486 | |
| Coefficient Of Variation | 154.11 | |
| Mean Deviation | 475,817 | |
| Median | 217,101 | |
| Standard Deviation | 794,733 | |
| Sample Variance | 631.6B | |
| Range | 3.3M | |
| R-Value | 0.32 | |
| Mean Square Error | 604.7B | |
| R-Squared | 0.10 | |
| Significance | 0.21 | |
| Slope | 50,383 | |
| Total Sum of Squares | 10.1T |
Edesa Net Receivables History
About Edesa Biotech Financial Statements
Edesa Biotech stakeholders use historical fundamental indicators, such as Edesa Biotech's Net Receivables, to determine how well the company is positioned to perform in the future. Although Edesa Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in Edesa Biotech's assets and liabilities are reflected in the revenues and expenses on Edesa Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Edesa Biotech. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Receivables | 739.3 K | 518.9 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Edesa Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Edesa Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Edesa Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Edesa Biotech Stock:Check out the analysis of Edesa Biotech Correlation against competitors. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. Projected growth potential of Edesa fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Edesa Biotech assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Edesa Biotech using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Edesa Biotech's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Edesa Biotech's market price to deviate significantly from intrinsic value.
It's important to distinguish between Edesa Biotech's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Edesa Biotech should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Edesa Biotech's market price signifies the transaction level at which participants voluntarily complete trades.